Skip to main content
. Author manuscript; available in PMC: 2015 Jan 8.
Published in final edited form as: Am J Transplant. 2013 Sep 5;13(11):3021–3030. doi: 10.1111/ajt.12417

Figure 1. Anti-CD154 domain antibodies are functionally equivalent to Fc-intact anti-CD154 mAbs.

Figure 1

(A) On day 0, B6 mice were transplanted with BALB/c skin grafts and were treated with 107 BALB/c DST and/or 250 µg of CTLA4-Ig, MR-1, 7E1-G2b or CD154 dAbs where indicated. (B) Mice treated with CTLA4-Ig alone rejected skin grafts with an MST of 15.5 d. Addition of MR-1 prolonged MST to 33 days, whereas addition of 7E1-G2b or CD154 dAbs led to an MST of 37 and 31 days, respectively. Data are cumulative of three independent experiments with a total of fourteen to fifteen mice per group. *** = p < 0.001 compared to CTLA4-Ig alone. Comparisons between MR-1, 7E1-G2b and CD154 dAbs were not statistically significant.